Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28681)	4/13/1999 11:13:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Targretin has been used on a compassionate use basis for Head & Neck tumors and I suspect that it could be used on almost any cancer.

To: bob zagorin who wrote (28681)	4/13/1999 12:22:00 PM
From: Cheryl Galt	Respond to of 32384

Questions: -- > could Targretin be used in a terminal case on a humane basis right now? < That would be a good question to ask Ligand IR: -- Is Targretin or Panretin or LGD 1550 being supplied for compassionate use for any indications? Also, does anyone know ??? -- Is FDA approval needed to supply a non-approved drug for compassionate use? Of course, there are ongoing multi-center trials of Targretin and Panretin for some advanced cancers, so terminal patients could enroll in those trials -- with the advantage that the results would be monitored and tabulated. Another question for those in the know: -- Can a patient's doctor link up to a trial from an off-site location ----- for example from a state in which there is no regular trial site? ----- perhaps by tele-communication, or computer networking? Are such provisions in place, in the protocol rules? Cheryl